Blueprint Medicines Corp Stock Price on October 31, 2024
| BPMC Stock | USD 90.14 1.21 1.36% |
Below is the normalized historical share price chart for Blueprint Medicines Corp extending back to April 30, 2015. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Blueprint Medicines stands at 90.14, as last reported on the 21st of December, with the highest price reaching 90.99 and the lowest price hitting 87.99 during the day.
If you're considering investing in Blueprint Stock, it is important to understand the factors that can impact its price. At this point, Blueprint Medicines is very steady. Blueprint Medicines Corp secures Sharpe Ratio (or Efficiency) of 0.0124, which signifies that the company had a 0.0124% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Blueprint Medicines Corp, which you can use to evaluate the volatility of the firm. Please confirm Blueprint Medicines' Risk Adjusted Performance of 0.0114, downside deviation of 2.54, and Mean Deviation of 1.71 to double-check if the risk estimate we provide is consistent with the expected return of 0.0297%.
The current year's Stock Based Compensation To Revenue is expected to grow to 0.52, whereas Total Stockholder Equity is forecasted to decline to about 124.1 M. . At present, Blueprint Medicines' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 44.91, whereas Price To Sales Ratio is forecasted to decline to 21.28. Blueprint Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 30th of April 2015 | 200 Day MA 96.7052 | 50 Day MA 92.2616 | Beta 0.59 |
Blueprint |
Sharpe Ratio = 0.0124
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BPMC |
Estimated Market Risk
| 2.4 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Blueprint Medicines is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Blueprint Medicines by adding Blueprint Medicines to a well-diversified portfolio.
Price Book 18.0405 | Enterprise Value Ebitda (11.22) | Price Sales 13.0045 | Shares Float 62.8 M | Wall Street Target Price 125.579 |
Related Headline
Day One Headline on 31st of October 2024
Disposition of 500 shares by Blackman Samuel C. of Day One a... by Blackman Samuel C.
Filed transaction by Day One Biopharmaceuticals Officer: Head Of R&d. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Blueprint Medicines Valuation on October 31, 2024
It is possible to determine the worth of Blueprint Medicines on a given historical date. On October 31, 2024 Blueprint was worth 89.23 at the beginning of the trading date compared to the closed value of 87.51. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Blueprint Medicines stock. Still, in general, we apply an absolute valuation method to find Blueprint Medicines' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Blueprint Medicines where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Blueprint Medicines' related companies.
| Open | High | Low | Close | Volume | |
| 90.92 | 94.98 | 88.80 | 89.24 | 1,913,963 | |
10/31/2024 | 89.23 | 89.61 | 87.31 | 87.51 | 834,973 |
| 87.53 | 90.85 | 87.28 | 90.70 | 619,676 |
| Backtest Blueprint Medicines | | | Blueprint Medicines History | | | Blueprint Medicines Valuation | Previous | Next |
Blueprint Medicines Trading Date Momentum on October 31, 2024
| On November 01 2024 Blueprint Medicines Corp was traded for 90.70 at the closing time. The top price for the day was 90.85 and the lowest listed price was 87.28 . The trading volume for the day was 619.7 K. The trading history from November 1, 2024 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 3.65% . The overall trading delta against the current closing price is 16.64% . |
Blueprint Medicines Corp Fundamentals Correlations and Trends
By evaluating Blueprint Medicines' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Blueprint Medicines' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Blueprint financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Blueprint Medicines Stock history
Blueprint Medicines investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Blueprint is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Blueprint Medicines Corp will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Blueprint Medicines stock prices may prove useful in developing a viable investing in Blueprint Medicines
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 60.6 M | 43.6 M | |
| Net Loss | -501.8 M | -476.7 M |
Blueprint Medicines Quarterly Net Working Capital |
|
Blueprint Medicines Stock Technical Analysis
Blueprint Medicines technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Blueprint Medicines Period Price Range
Low | December 21, 2024
| High |
0.00 | 0.00 |
Blueprint Medicines Corp cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Blueprint Medicines December 21, 2024 Market Strength
Market strength indicators help investors to evaluate how Blueprint Medicines stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Blueprint Medicines shares will generate the highest return on investment. By undertsting and applying Blueprint Medicines stock market strength indicators, traders can identify Blueprint Medicines Corp entry and exit signals to maximize returns
Blueprint Medicines Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Blueprint Medicines' price direction in advance. Along with the technical and fundamental analysis of Blueprint Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Blueprint to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0114 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.06) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0037 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |